AEG35156

Generic Name: AEG35156

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Background: A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytot...

Indication: Investigated for use/treatment in cancer/tumors (unspecified) and leukemia (myeloid).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: AEG35156

First Posted Date: 2009-11-23

Last Posted Date: 2011-07-13

Lead Sponsor: Aegera Therapeutics

Target Recruit Count: 60

Registration Number: NCT01018069

Locations: 🇩🇪
2. Medizinische Klinik und Poliklinik im Stadtischen Krankenhaus Kile GmgH, Kiel, Germany
🇺🇸
Rocky Mountain Blood & Marrow Transplant Program, Denver, Colorado, United States
🇺🇸
MD Anderson Cancer Center University of Texas, Houston, Texas, United States

and more 15 locations

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Phase 1

Terminated

Conditions: Human Mammary Carcinoma

First Posted Date: 2007-11-15

Last Posted Date: 2009-12-02

Lead Sponsor: Aegera Therapeutics

Target Recruit Count: 61

Registration Number: NCT00558545

Locations: 🇺🇸
Tyler Cancer Center, Tyler, Texas, United States
🇺🇸
Cancer Centers of Florida, P.A., Ocoee, Florida, United States
🇺🇸
Dayton Oncology & Hematology, P.A., Dayton, Ohio, United States

and more 7 locations

A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2007-11-15

Last Posted Date: 2009-07-30

Lead Sponsor: Aegera Therapeutics

Target Recruit Count: 54

Registration Number: NCT00558922

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Central Indiana Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States

and more 3 locations

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreas
Carcinoma

First Posted Date: 2007-11-14

Last Posted Date: 2009-12-01

Lead Sponsor: Aegera Therapeutics

Target Recruit Count: 48

Registration Number: NCT00557596

Locations: 🇺🇸
Scottsdale Healthcare - SHEA, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
Arizona Cancer Center - University of Arizona, Tucson, Arizona, United States

and more 1 locations

Study of XIAP Antisense for Advanced Cancers

Phase 1

Terminated

Conditions: Advanced Cancer

First Posted Date: 2006-10-11

Last Posted Date: 2008-08-21

Lead Sponsor: Aegera Therapeutics

Target Recruit Count: 30

Registration Number: NCT00385775

Locations: 🇬🇧
Christie Hospital NHS Trust, Manchester, United Kingdom

AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2006-09-07

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 27

Registration Number: NCT00372736

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
McGill University - Dept. Oncology, Montreal, Quebec, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

AEG35156 and Docetaxel in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: AEG35156
Drug: docetaxel

First Posted Date: 2006-07-27

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 10

Registration Number: NCT00357747

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
McGill University - Dept. Oncology, Montreal, Quebec, Canada

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy